FAM-CAPD: Family Assessment of Pediatric Delirium

Sponsor
University of Calgary (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05220761
Collaborator
Alberta Children's Hospital Research Institute (Other)
235
2
9.7
117.5
12.1

Study Details

Study Description

Brief Summary

In this study the investigators will assess the validity, reliability and acceptability of utilizing family members to complete a delirium screen using the Cornell Assessment of Pediatric Delirium (CAPD).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cornell Assessment of Pediatric Delirium

Detailed Description

Diagnosing delirium in the heterogenous PICU population is difficult. There is significant variability in pre-morbid neurodevelopmental status in children due to both age-related development as well as pre-morbid cognitive delay. The Cornell Assessment of Pediatric Delirium (CAPD) has been validated in children of all ages and developmental stages. Several confounding factors have been identified that decrease the specificity of delirium detection and include confounding syndromes (i.e. iatrogenic withdrawal syndrome), pre-existing neuro-cognitive delay, and the specialty, experience and training of the assessor. Furthermore, pediatric critical care nurses have many competing interests in prioritizing care for their patients and can struggle with trying to familiarize themselves with the concept of delirium. This is a recognized barrier to routine compliance with delirium screening in PICUs. Family screening may be extremely valuable in early identification of delirium. This has been demonstrated in the critically ill adult population, however, with respect to family detection of delirium in their own children, the reliability of a pediatric screening tool has not been evaluated.

The proposed work is designed to improve both processes of care, by improving delirium screening, and patient outcomes by engaging families in the identification, prevention and management of delirium, in critically ill children.

This study will be conducted at 2 academic PICUs in Canada. Eligible children will be consented and enrolled. Parents/caregivers will be given brief education on delirium assessment and then complete a family tool based on the Cornell Assessment of Pediatric Delirium (CAPD). This will then be validated against the RN completed CAPD.

In order to also assess the acceptability of family detection of PICU delirium interviews of family members and focus groups of HCP will be conducted using qualitative methodology to determine acceptance and feasibility and to guide future knowledge translation work.

Study Design

Study Type:
Observational
Anticipated Enrollment :
235 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
FAM-CAPD: Family Assessment of Pediatric Delirium
Actual Study Start Date :
Aug 9, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Validity of delirium screening by caregivers [1-28 days]

    Evaluate the validity of delirium screening by family or caregivers using the cornel assessment of pediatric delirium on their own children while they are admitted to a PICU

Secondary Outcome Measures

  1. Healthcare professional acceptability of family administered delirium assessment [Up to 1 year]

    Explore health care professionals perception and acceptability of family administered delirium assessment in critically ill children

  2. Family/caregiver acceptability of family administered delirium assessment [Up to 1 year]

    Explore family member/caregiver perception and acceptability of family administered delirium assessment in critically ill children

  3. Correlation between absolute score of Richmond Agitation and sedation Scale and State Behavioral Scale. [1-28 days]

    To assess the correlation between the absolute score of the Richmond Agitation and Sedation Scale and the State Behavioral Scale for each child in assessing sedation and agitation in critically ill children

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admitted to Alberta Children's Hospital or McMaster Children's Hospital PICU during study enrollment period

  • Anticipated length of stay in PICU >/=48 hours

  • Substitute decision maker with the ability to provide informed consent

  • Primary caregiver available for CAPD assessments,

  • Primary caregiver is defined as the person primarily responsible for the care and upbringing of a child and could include: Parents, designated older sibling, foster parents/guardians, or grandparents, who fulfill this definition. There may be more than one primary caregiver for each child

  • Translated CAPD and educational materials available in primary spoken language (French, Chinese, Italian or Spanish)

Exclusion Criteria:
  1. Anticipated discharge/transfer within 24 hours II. Family member unable to understand the instructions for CAPD assessment
  1. This will be identified by the research assistant in collaboration with the bedside care team. i.e. language/cognitive barrier III. Child in irreversible coma (i.e. persistent vegetative state, RASS -4/SBS -2 or less and not reversible)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laurie A. Lee Calgary Alberta Canada T2T 5T3
2 McMaster Children's Hospital Hamilton Ontario Canada

Sponsors and Collaborators

  • University of Calgary
  • Alberta Children's Hospital Research Institute

Investigators

  • Principal Investigator: Laurie A. Lee, MN, University of Calgary

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Laurie Lee, Adjunct Clinical Associate, University of Calgary
ClinicalTrials.gov Identifier:
NCT05220761
Other Study ID Numbers:
  • REB 20-2149
First Posted:
Feb 2, 2022
Last Update Posted:
Feb 2, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2022